跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
P29
首页
药物
P29
P29
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Preparation method of echinococcus multilocularis recombinant P29 protein monoclonal antibody
申请人: UNIV NINGXIA MEDICAL
优先权: 2024
CN
Preparation and application of echinococcus granulosus recombinant antigen P29 monoclonal antibody
申请人: UNIV NINGXIA MEDICAL
优先权: 2023
CN
Construction and application of medical intermediate P29 eukaryotic expression engineering bacteria
申请人: UNIV HUBEI TECHNOLOGY
优先权: 2026
CN
Smeglutide intermediate P29 genetically engineered bacterium as well as construction and application thereof
申请人: UNIV HUBEI TECHNOLOGY
优先权: 2025
CN
Immune response effect generated after mouse immunization of echinococcosis-resistant recombinant vaccine P29 epitope peptide
申请人: UNIV NINGXIA MEDICAL
优先权: 2022
CN
一种细粒棘球蚴重组抗原P29优势表位肽筛选及应用
申请人: 宁夏医科大学
优先权: 2022
CN
结核分枝杆菌特异性CD8<Sup>+</Sup>T细胞表位肽P29及其应用
申请人: 南方医科大学
优先权: 2014
CN
METHODS AND COMPOSITIONS OF VIRUS-LIKE PARTICLES OF CYTOPLASMIC TYPE CITRUS LEPROSIS VIRUS FOR NANOTECHNOLOGY APPLICATIONS
申请人: UNIV CALIFORNIA
优先权: 2023
US
药物
反馈